Marc Gleichmann
About Marc Gleichmann
Current Title and Role
Marc Gleichmann serves as the Executive Director, Early Clinical Development Neuroscience at Bristol Myers Squibb. In this role, he is based in San Diego, California, and focuses on advancing clinical programs and studies within the field of neuroscience.
Previous Experience at Celgene
Before joining Bristol Myers Squibb, Marc Gleichmann was with Celgene as the Senior Director Clinical Development. He held this position from 2017 to 2020 in the Greater San Diego Area. During his tenure, he was responsible for overseeing clinical development programs in various therapeutic areas.
Roles in Clinical Development
Marc Gleichmann has an extensive background in clinical development. He worked at Ionis Pharmaceuticals, Inc. as Director of Clinical Development from 2015 to 2017 in Carlsbad. Prior to that, he was the Medical Director at EMD Serono, Inc., from 2012 to 2015. His earlier positions include Senior Clinical Research Scientist at MerckSerono SA in Geneva, Switzerland, from 2010 to 2012, and Visiting Fellow at the National Institute on Aging, NIH, from 2004 to 2010.
Long-Standing Academic and Clinical Background
Marc Gleichmann began his career in academia and clinical practice. He served as a Clinical Fellow (Assistenzarzt) at the Department of Neurology, University of Tuebingen, from 1996 to 2004. His educational journey in medicine started at Heinrich-Heine-Universität Düsseldorf, where he completed his MD from 1989 to 1996.
Expertise in Neurological Clinical Programs
With a strong foundation in clinical neurology and academic research, Marc Gleichmann has significant experience in neuromuscular disorders. He has been involved in clinical programs targeting dementia, movement disorders, multiple sclerosis, and neuromuscular disorders across Phase 1-3 studies. His work emphasizes data-driven decision-making to translate scientific discoveries into innovative drug therapies.